Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Dag Torfoss"'
Autor:
Trine-Lise Larsen, Marte Svalastoga, Jorunn Brekke, Tone Enden, Hege Frøen, Herish Garresori, Eva Marie Jacobsen, Petter Quist Paulsen, Alina Carmen Porojnicu, Anne Hansen Ree, Dag Torfoss, Elin Osvik Velle, Hilde Skuterud Wik, Waleed Ghanima, Per Morten Sandset, Anders Erik Astrup Dahm
Publikováno v:
Thrombosis Research.
Autor:
Anders Erik Astrup Dahm, Dag Torfoss, Eva-Marie Jacobsen, Hege Frøen, Per Morten Sandset, Waleed Ghanima, Trine-Lise Larsen
Publikováno v:
Tidsskrift for Den norske legeforening.
Autor:
Trine-Lise Larsen, Jorunn Brekke, Herish Garresori, Hege Frøen, Eva-Marie Jacobsen, Dag Torfoss, Hilde Skuterud Wik, Tone Ronnaug Enden, Alina Carmen Porojnicu, Petter Quist-Paulsen, Elin Velle, Per Morten Sandset, Anne Hansen Ree, Anders E.A. Dahm
Publikováno v:
Blood. 140:11366-11367
Autor:
Trine‐Lise Larsen, Herish Garresori, Jorunn Brekke, Tone Enden, Hege Frøen, Eva Marie Jacobsen, Petter Quist‐Paulsen, Alina Carmen Porojnicu, Anne Hansen Ree, Dag Torfoss, Elin Osvik Velle, Hilde Skuterud Wik, Waleed Ghanima, Per Morten Sandset, Anders Erik Astrup Dahm
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCE. 20(8)
Autor:
Per Morten Sandset, Petter Quist Paulsen, Anne Hansen Ree, Elin Osvik Velle, Waleed Ghanima, Herish Garresori, Trine-Lise Hannevik, Anders E.A. Dahm, Hege Frøen, Eva Marie Jacobsen, Tone Enden, Jorunn Brekke, Hilde Skuterud Wik, Alina Carmen Porojnicu, Dag Torfoss
Publikováno v:
Thrombosis research. 196
Introduction The direct oral anti-coagulants (DOAC) edoxaban and rivaroxaban are suggested treatment alternatives for cancer-associated venous thromboembolism (VTE) together with low molecular-weight heparins. New studies indicate that the DOAC apixa
Autor:
Dag Torfoss, Harald Holte, Sigbjørn Smeland, Sunniva Fagerås Røst, Eldbjørg Vorkinn, Stein Kvaløy
Publikováno v:
Tidsskrift for Den norske legeforening.
Autor:
Hege Frøen, Tone Enden, Hilde Skuterud Wik, Waleed Ghanima, Dag Torfoss, Anders E.A. Dahm, Alina Carmen Porojnicu, Trine-Lise Hannevik, Anne Hansen Ree, Jorunn Brekke, Per Morten Sandset, Herish Garresori, Eva-Marie Jacobsen, P.Q. Paulsen, Elin Osvik Velle
Publikováno v:
Thrombosis Research. 200:S15-S16
Autor:
Anne Hansen Ree, Eva-Marie Jacobsen, Per Morten Sandset, Jorunn Brekke, Tone Enden, Waleed Ghanima, Alina Carmen Porojnicu, Hilde Skuterud Wik, Petter Quist-Paulsen, Herish Garresori, Trine-Lise Hannevik, Hege Frøen, Elin Osvik Velle, Anders Ea Dahm, Dag Torfoss
Publikováno v:
Blood. 138:3231-3231
Background: Apixaban is a treatment option for venous thromboembolism (VTE) in cancer patients. There are no data on the effect of low dose apixaban after 6 months treatment. We wanted to assess the efficacy and safety of apixaban 2.5 mg twice daily
Autor:
Arne Kolstad, Harald Holte, Alexander Fosså, Grete Fossum Lauritzsen, Peter Gaustad, Dag Torfoss
Publikováno v:
Haematologica, Vol 92, Iss 1 (2007)
We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis shoul
Externí odkaz:
https://doaj.org/article/b015ac6e55ec45e9b212553b2502907b
Publikováno v:
Tidsskrift for Den norske legeforening.